KLF4-dependent, PPARγ-induced expression of GPA33 in colon cancer cell lines

International Journal of Cancer

Volumn 125, Issue 12, 2009, Pages 2802-2809

  Rageul, Julie ^a   Mottier, Stéphanie ^a   Jarry, Anne ^b   Shah, Yatrik ^c   Théoleyre, Sandrine ^a   Masson, Damien ^b   Gonzalez, Frank J ^c   Laboisse, Christian L ^b   Denis, Marc G ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Colon cancer; GPA33; KLF4; PPAR ; Regulation

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOKERATIN 19; GLYCOPROTEIN; GLYCOPROTEIN A33; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A; GPA33 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MEMBRANE PROTEIN;

ARTICLE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; CHROMATIN IMMUNOPRECIPITATION; COLON TUMOR; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MEMBRANE GLYCOPROTEINS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 72449151427     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24683     Document Type: Article

References (56)

1. Lefebvre M, Paulweber B, Fajas L, Woods J, McCrary C, Colombel JF, Najib J, Fruchart JC, Datz C, Vidal H, Desreumaux P, Auwerx J. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 1999;162:331-340 (Pubitemid 29447426)
2. Su W, Bush CR, Necela BM, Calcagno SR, Murray NR, Fields AP, Thompson EA. Differential expression, distribution, and function of PPAR-γ in the proximal and distal colon. Physiol Genomics 2007;30:342-353 (Pubitemid 47296193)
3. Thompson EA. PPARgamma physiology and pathology in gastrointestinal epithelial cells. Mol Cells 2007;24:167-176
4. Lefebvre AM, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferator- activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/1 mice. Nat Med 1998;4:1053-1057 (Pubitemid 28417338)
5. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM. Activators of the nuclear receptor PPAR-gamma enhance colon polyp formation. Nat Med 1998; 4:1058-1061 (Pubitemid 28417339)
6. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003;9:1-9. (Pubitemid 36109710)
7. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004;4:61-70. (Pubitemid 38082154)
8. Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S, Miwa K. Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 2004; 25:631-639
9. Sarraf P, Mueller E, Jones D, King FJ, Deangelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998;4:1046-1052 (Pubitemid 28417337)
10. Gupta RA, Brockman JA, Sarraf P, Willson TM, Dubois RN. Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem 2001;276:29681-29687 (Pubitemid 37385035)
11. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai M, Sekihara H, Nakagama H. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361-367 (Pubitemid 36169253)
12. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, Hosokawa M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001;61:2424-2428 (Pubitemid 32685818)
13. Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C, Nambiar P, Rosenberg DW, Bronson RT, Edelmann W, Kucherlapati R, Gonzalez FJ, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 2002;99:13771-13776 (Pubitemid 35215456)
14. Augeron C, Laboisse CL. Emergence of permanently differentiated cell clones in a human colonic cancer cell line in culture after treatment with sodium butyrate. Cancer Res 1984;44:3961-3969 (Pubitemid 14041623)
15. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu G-F, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1997;94:469-474
16. Johnstone CN, Tebbutt NC, Abud HE, White SJ, Stenvers KL, Hall NE, Cody SH, Whitehead RH, Catimel B, Nice EC, Burgess AW, Heath JK. Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2000;279:G500-G510.
17. Catimel B, Ritter G, Welt S, Old LJ, Cohen L, Nerrie MA, White SJ, Heath JK, Demediuk B, Domagala T, Lee FT, Scott AM, et al. Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium. J Biol Chem 1996;271:25664-25670 (Pubitemid 26337947)
18. Ritter G, Cohen LS, Nice EC, Catimel B, Burgess AW, Moritz RL, Ji H, Heath JK, White SJ, Welt S, Old LJ, Simpson RJ. Characterization of posttranslational modifications of human A33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. Biochem Biophys Res Commun 1997;236:682-686
19. Garin-Chesa PSJ, Welt S, Real FX, Rettig WJ, Old LJ. Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol 1996;9:465-471 (Pubitemid 26323936)
20. Sakamoto J, Kojima H, Kato J, Hamashima H, Suzuki H. Organ-specific expression of the intestinal epithelium-related antigen A33, a cell surface target for antibody-based imaging and treatment in gastrointestinal cancer. Cancer Chemother Pharmacol 2000; 46(Suppl):S27-S32. (Pubitemid 30835952)
21. Scott AM, Lee F-T, Jones R, Hopkins W, Macgregor D, Cebon JS, Hannah A, Chong G, Paul U, Papenfuss A, Rigopoulos A, Sturrock S; et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005; 11:4810-4817 (Pubitemid 41568167)
22. Welt S, Ritter G, Williams C, Cohen LS, John M, Jungbluth A, Richards EA, Old LJ, Kemeny NE. Phase I study of anticolon cancer humanized antibody A33. Clin Cancer Res 2003;9:1338-1346
23. Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, Paul U, Murphy R, Wirth V, et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res 2005;11:4818-4826 (Pubitemid 41568168)
24. Dang DT, Pevsner J, Yang VW. The biology of the mammalian Kruppel-like family of transcription factors. Int J Biochem Cell Biol 2000;32:1103-1121 (Pubitemid 32008299)
25. Bieker JJ. Kruppel-like factors: three fingers in many pies. J Biol Chem 2001;276:34355-34358 (Pubitemid 37384419)
26. Shields JM, Christy RJ, Yang VW. Identification and characterization of a gene encoding a gut-enriched Kruppel-like factor expressed during growth arrest. J Biol Chem 1996;271:20009-20017 (Pubitemid 26281749)
27. Flandez M, Guilmeau S, Blache P, Augenlicht LH. KLF4 regulation in intestinal epithelial cell maturation. Exp Cell Res 2008;314:3712-3723
28. Evans PM, Liu C. Roles of Krupel-like factor 4 in normal homeostasis, cancer and stem cells. Acta Biochim Biophys Sin (Shanghai) 2008;40:554-564 (Pubitemid 352009081)
29. Blanchot-Jossic F, Jarry A, Masson D, Bach-Ngohou K, Paineau J, Denis MG, Laboisse CL, Mosnier JF. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 2005;207:156-163 (Pubitemid 41404146)
30. Mao Z, Shan S, Zhu Y, Yi X, Zhang H, Shang Y, Tong T. Transcriptional regulation of A33 antigen expression by gut-enriched Kruppel-like factor. Oncogene 2003;22:4434-4443 (Pubitemid 36897974)
31. Bouancheau D, Buecher B, Jarry A, Simon B, Masson D, Cassagnau E, Hamelin R, Laboisse CL, Bezieau S, Denis MG. The PPAR γ K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment. Cancer Lett 2005; 224:111-116
32. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, Sporn MB. A new ligand for the peroxisome proliferator-activated receptor- gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999;59:5671-5673
33. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D, Glass CK. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999;400:378-382 (Pubitemid 29344205)
34. Johnstone CN, White SJ, Tebbutt NC, Clay FJ, Ernst M, Biggs WH, Viars CS, Czekay S, Arden KC, Heath JK. Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression. J Biol Chem 2002;277:34531-34539 (Pubitemid 35056277)
35. Chen ZY, Shie J-L, Tseng C-C. Up-regulation of gut-enriched Krüppel-like factor by interferon-γ in human colon carcinoma cells. FEBS Lett 2000;477:67-72. (Pubitemid 30438859)
36. Shie J-L, Chen ZY, O'brien MJ, Pestell RG, Lee M-E, Tseng C-C. Role of gut-enriched Kruppel-like factor in colonic cell growth and differentiation. Am J Physiol Gastrointest Liver Physiol 2000;279:G806-G814.
37. Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH, Biggs JR, Kraft AS, Yang VW. The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J Biol Chem 2000;275:18391-18398 (Pubitemid 30414796)
38. Chen X, Whitney EM, Gao SY, Yang VW. Transcriptional profiling of Krüppel-like factor 4 reveals a function in cell cycle regulation and epithelial differentiation. J Mol Biol 2003;326:665-677 (Pubitemid 36279310)
39. Shie JL, Chen ZY, Fu M, Pestell RG, Tseng CC. Gut-enriched Kruppel-like factor represses cyclin D1 promoter activity through Sp1 motif. Nucleic Acids Res 2000;28:2969-2976 (Pubitemid 30599273)
40. Kitamura S, Miyazaki Y, Hiraoka S, Nagasawa Y, Toyota M, Takakura R, Kiyohara T, Shinomura Y, Matsuzawa Y. PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. Int J Cancer 2001;94:335-342 (Pubitemid 32906062)
41. Gupta RA, Sarraf P, Brockman JA, Shappell SB, Raftery LA, Willson TM, Dubois RN. Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J Biol Chem 2003;278:7431-7438 (Pubitemid 36800748)
42. Sunami E, Tsuno NH, Kitayama J, Saito S, Osada T, Yamaguchi H, Tomozawa S, Tsuruo T, Shibata Y, Nagawa H. Decreased synthesis of matrix metalloproteinase-7 and adhesion to the extracellular matrix proteins of human colon cancer cells treated with troglitazone. Surg Today 2002;32:343-350 (Pubitemid 34671267)
43. Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, Gumucio DL, Marin HE, Peters JM, Young HA, Gonzalez FJ. Peroxisome proliferator activated receptor g in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 2006;55:1104-1113 (Pubitemid 44085676)
44. Chen ZY, Tseng C-C. 15-Deoxy-{Delta}12,14 prostaglandin J2 upregulates Kruppel-like factor 4 expression independently of peroxisome proliferator-activated receptor g by activating the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signal transduction pathway in HT-29 colon cancer cells. Mol Pharmacol 2005;68:1203-1213
45. Chen ZY, Rex S, Tseng C-C. Kruppel-like factor 4 is transactivated by butyrate in colon cancer cells. J Nutr 2004;134:792-798 (Pubitemid 38456245)
46. Dang DT, Bachman KE, Mahatan CS, Dang LH, Giardiello FM, Yang VW. Decreased expression of the gut-enriched Kruppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients. FEBS Lett 2000;476:203-207
47. Ghaleb AM, Yang VW. The pathobiology of Kruppel-like factors in colorectal cancer. Curr Colorectal Cancer Rep 2008;4:59-64.
48. Antoniw P, Farnsworth AP, Turner A, Haines AM, Mountain A, Mackintosh J, Shochat D, Humm J, Welt S, Old LJ, Yarranton GT, King DJ. Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). Br J Cancer 1996;74:513-524 (Pubitemid 26279044)
49. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994;12:1561-1571 (Pubitemid 24244990)
50. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996;14:1787-1797 (Pubitemid 26187992)
51. Welt S, Ritter G, Williams C, Cohen LS, Jungbluth A, Richards EA, Old LJ, Kemeny NE. Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2003;9:1347-1353 (Pubitemid 36418385)
52. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002;8:395-399
53. Zhang YQ, Tang XQ, Sun L, Dong L, Qin Y, Liu HQ, Xia H, Cao JG. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 2007;13:1534-1540 (Pubitemid 46672661)
54. Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, et al. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 2008;14:6478-6486
55. Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM. Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 2007;11:395-406. (Pubitemid 46670076)
56. Yu HN, Noh EM, Lee YR, Roh SG, Song EK, Han MK, Lee YC, Shim IK, Lee SJ, Jung SH, Kim JS, Youn HJ. Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells. Biochem Biophys Res Commun 2008;377:242-247